

ASX ANNOUNCEMENT**ADMEDUS SPP WELL SUPPORTED, RAISES \$10.1M**

- Admedus raises total of \$18.4M in placement and SPP
- Scaled back SPP raises \$10.1M
- Admedus in a strong financial position

Brisbane, Australia, 6th June 2014

Admedus (ASX: AHZ) today announced strong support for its Share Purchase Plan (SPP) pursuant to which the Company has received applications of \$11.8 million. The Company has decided to scale back applications such that a total of \$10.1M is raised through the SPP. In combination with the recent share placement, a total of \$18.4M has been raised, which places the company in a strong financial position to grow revenue and progress the development programmes.

"We welcome the new shareholders that invested via the placement and thank our existing shareholders for their strong support with the SPP" said Admedus CEO Mr. Lee Rodne. "The Company is now in a strong financial position to expand our marketing activity for CardioCel® in Europe and the US and to progress our therapeutic vaccines into key clinical studies."

The funds raised in the recent placement and SPP will be used to:

- Expand sales and marketing efforts in Europe and the US for CardioCel® our lead product from Admedus' regenerative tissue portfolio
- Undertake additional clinical studies that support the use of CardioCel® for an expanded range of indications in cardiovascular surgery
- Expand the regenerative tissue portfolio and explore the use of ADAPT® prepared tissue for additional surgical applications that have the potential to increase revenue in the future
- Progress the therapeutic vaccines programme for HSV-2 into a Phase II clinical study and complete the HPV therapeutic vaccine preclinical programme, which will then progress to a Phase I/II clinical study. This investment will result in an increased ownership in Admedus Vaccines

"These additional funds will enable our marketing and sales teams to continue to drive revenue for the company in key markets, as well as to undertake additional studies that will further build on the credentials of our platform technologies and expand our regenerative tissue and therapeutic vaccine portfolios", added Mr. Rodne.

Admedus will also explore additional approvals for CardioCel® in other significant global markets. Over 250 patients have now been implanted with CardioCel®, with data showing no detectable calcification over 6 years post implantation and no need for 're-do' or follow up surgeries.

New shares from the SPP will be issued on the 11th of June 2014 and holding statements will be sent to shareholders on the 12th of June 2014. Refunds will be posted back to shareholders within the next two weeks

Morgans Corporate Limited was lead manager to the placement and SPP.

For more information, please contact:

Dr. Julian Chick, Chief Operating Officer Admedus Limited Tel: +61 3 9620 5454

Media:

Tahlia Weston

Buchan Consulting

+61 3 8866 1203

tweston@buchanwe.com.au

About Admedus Limited

Admedus (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Admedus also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com

Admedus Regen

Admedus Regen started as a research program in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT[®] Tissue Engineering Process. The lead program, CardioCel[®] is approved in Europe and is being used in Australia under the Authorised Prescriber Scheme. CardioCel[®] is a cardiovascular scaffold used to repair paediatric and adult heart deformities. These deformities range from routine "hole in the heart" operations to major vessel outflow tract repairs. The CardioCel[®] scaffold may also be used to repair leaking heart valves in paediatric and adult patients. CardioCel[®] has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration*, suggesting that CardioCel[®] facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

The division is based on the patented ADAPT[®] Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT[®] technology is used to process xenograft tissues to produce unique implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation and has the potential to replace many of the products that surgeons currently use for soft tissue repair.

* Körbling&Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003,

About Admedus Vaccines

Admedus Vaccines was founded in 2000 by the founder inventor Professor Ian Frazer as a private unlisted company, to develop and commercialise patented technology for improving immune responses to DNA vaccines licensed by UniQuest Pty Ltd and developed at the University of Queensland. The company has laboratories within the Translational Research Institute at the Princess Alexandra Hospital in Brisbane, working in collaboration with the University of Queensland's Diamantina Institute. The company's overall objective is to utilise its unique optimisation technology to produce prophylactic and/or therapeutic DNA vaccines for a range of infectious diseases and cancers in humans. Product development is currently focused on Herpes virus vaccines.

About Admedus Vaccines optimised technology

Admedus Vaccines has 6 granted US patents protecting its codon optimisation DNA technology, which enhances protein expression in the cell or tissue targeted and results in an improved humoral response. The second component of the technology, also patent protected, is to use a mixture of DNAs encoding ubiquitinated and non ubiquitinated proteins. This strategy enhances the degradation of the protein and optimises T cell responses, while preserving structural epitopes necessary for B cell responses, resulting in vaccines with both prophylactic and therapeutic potential.

About Genital Herpes

This disease often results in recurrent painful sores in the genital area. HSV-2 is the major causative agent of genital herpes. As well as pain and discomfort to infected individuals, the virus can have serious health implications for babies born to infected women. Herpes is also believed to aid in the transmission of HIV. Current Herpes treatment involves the use of antiviral drugs which can reduce, but not eliminate, outbreaks and shedding and therefore do not prevent spread of the disease. According to research reported in Biomed Central's journal BMC Infectious Diseases, the economic burden of genital HSV infection and resulting complications has been estimated to be greater than \$1 billion annually in the USA alone.